Longitude Capital Entities Report Holdings in CG Oncology, Inc.

Longitude Capital Partners IV, LLC, Longitude Venture Partners IV, L.P., Longitude Prime Partners, LLC, and Longitude Prime Fund, L.P., along with managing members Patrick G. Enright and Juliet Tammenoms Bakker, have filed a Schedule 13D regarding their holdings in CG Oncology, Inc. The filing discloses that these entities collectively own approximately 6.0% of CG Oncology's common stock. The shares were acquired through various transactions, including purchases of Series E and Series F redeemable convertible preferred stock, and subsequent conversions into common stock following CG Oncology's initial public offering. The Reporting Persons hold these securities for general investment purposes and may acquire or dispose of additional shares based on market conditions and other factors. The filing also includes details of an Amended and Restated Investors' Rights Agreement, which provides certain registration rights to the stockholders.